Gossamer Bio, Inc. (GOSS): Total Assets
$172.25M
As of 2025-12-31
$76.87M
As of 2026-06-30
-14.2%
3-year compound annual growth
-20.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $172.25M | -45.4% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $315.29M | +1.1% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $311.92M | +14.5% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $272.45M | -20.7% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $343.66M | -36.3% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $539.43M | +26.4% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $426.60M | +78.2% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $239.42M | n/a | 2020-03-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $808.06M | +76.5% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $76.82M | +1.6% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $154.69M | +117.6% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $61.78M | -33.1% |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗